AnaptysBio Balance Sheet
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio financial position
At the end of fiscal 2025, AnaptysBio reported total assets of $364.4 million, down 24.7% from a year earlier against total liabilities of $327.2 million. Shareholders' equity stood at $37.2 million, or 10.2% of assets. The company held $138.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.07, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 138.20M | 23.08M | 35.97M | 71.31M | 495.73M | 250.46M | 171.02M | 113.60M | 81.19M | 51.23M |
| Short-Term Investments | 73.44M | 262.29M | 354.94M | 369.93M | 52.37M | 143.20M | 203.21M | 313.49M | 167.22M | 0 |
| Receivables | 33.85M | 40.77M | 6.85M | 1.42M | 876.00K | 0 | 0 | 0 | 0 | 1.23M |
| Total Current Assets | 350.25M | 431.88M | 406.83M | 447.20M | 553.88M | 396.56M | 377.73M | 434.22M | 252.70M | 58.21M |
| Property, Plant & Equipment | 111.00K | 131.00K | 2.10M | 2.09M | 2.28M | 1.78M | 1.62M | 1.45M | 665.00K | 471.00K |
| Long-Term Investments | 0 | 35.47M | 27.03M | 142.94M | 67.10M | 17.55M | 54.30M | 73.13M | 75.90M | 0 |
| Total Assets | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M | 416.55M | 435.20M | 509.00M | 329.36M | 62.18M |
| Accounts Payable | 3.87M | 4.00M | 4.70M | 2.78M | 1.74M | 4.22M | 16.24M | 5.44M | 2.32M | 2.28M |
| Total Current Liabilities | 38.63M | 45.43M | 37.44M | 26.05M | 16.10M | 19.82M | 29.54M | 21.84M | 14.09M | 5.71M |
| Total Liabilities | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M | 19.82M | 30.19M | 22.63M | 21.78M | 100.43M |
| Shareholders' Equity | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M | 396.73M | 405.01M | 486.37M | 307.58M | -38.25M |
| Retained Earnings | -772.56M | -759.33M | -614.10M | -450.48M | -321.75M | -263.96M | -244.03M | -146.69M | -85.03M | -54.92M |
| Net Cash (Debt) | 211.64M | 285.37M | 390.90M | 441.24M | 548.10M | 393.65M | 374.23M | 427.08M | 248.41M | 51.23M |
| Shares Outstanding | 28.02M | 30.47M | 26.60M | 28.51M | 27.65M | 27.36M | 27.25M | 26.92M | 23.79M | 2.65M |
This table shows 10 annual periods of AnaptysBio's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a balance sheet?